This site contains promotional content intended for Healthcare Professionals in Ireland and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Area

Beyonttra
®
▼(acoramidis)

Post-hoc Analysis of Serum TTR

ATTRibute-CM: Mean change from baseline in serum TTR at Month 30 modified intention to treat (mITT).

Efficacy-exploratory-post-hoc

This was an exploratory endpoint. To be interpreted with caution due to small patient numbers and differences in characteristics between groups.

  • Blood samples from participants in ATTRibute-CM were taken  to measure mean change in serum TTR levels from baseline to month 30.
  • Participants were allowed to receive tafamidis 12 months after randomisation. At month 30, there was, on average, a 42% difference in serum TTR between participants in the placebo arm receiving tafamidis (n = 35), and those receiving acoramidis (n = 234).
Beyonttra®▼ (acoramidis) - All-cause mortality in the OLE
Learn more about the All-cause mortality in the open-label extension of Beyonttra® (acoramidis).
PP-BEY-IE-0037-1, November 2025
Beyonttra®▼ (acoramidis) - ATTRibute-CM Study Design
Explore more about the ATTRibute-CM Study Design of evaluating the efficacy & safety of acoramidis vs placebo.
PP-BEY-IE-0036-1, November 2025
Beyonttra®▼ (acoramidis) - Safety Profile
Learn more about the Safety Profile of Beyonttra® (acoramidis).
PP-BEY-IE-0033-1, November 2025

PP-BEY-IE-0042-1   |   November 2025

 

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professional are asked to report any suspected adverse reactions.